Anti-DBH Polyclonal Antibody for WB, IHC-P, ELISA - P09172

Core Product Specifications and Parameters

Biological Background: DBH Function and Localization

• Dopamine beta-hydroxylase (DBH), also known as dopamine beta-monooxygenase, catalyzes the conversion of dopamine to noradrenaline, a critical step in catecholamine neurotransmitter biosynthesis.
• DBH is a copper-containing monooxygenase that requires ascorbate (vitamin C) as a cofactor for its enzymatic activity.
• The protein localizes to secretory vesicles, particularly chromaffin granules, where it exists both as a soluble luminal enzyme and as a membrane-bound form via a signal-anchor transmembrane helix.
• DBH is a glycoprotein with multiple disulfide bonds, and its three-dimensional structure has been determined.
• Mutations in the DBH gene are associated with dopamine beta-hydroxylase deficiency, an autonomic disorder.
• DBH is secreted into the bloodstream following exocytosis of chromaffin granules and can serve as a marker for sympathetic nerve activity.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 388-617 within the catalytic domain of human DBH, providing a region rich in potential epitopes for polyclonal antibody production.
• For Western blotting, expect a band at approximately 69 kDa; validate specificity using positive controls such as adrenal medulla lysates or sympathetic neuron cultures.
• This antibody has been reported to work in WB, IHC-P, and ELISA; consider titrating dilutions for each application to optimize signal-to-noise ratio.
• Cross-reactivity with mouse and rat orthologs enables multispecies studies, but confirm reactivity in the relevant sample system before large-scale experiments.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive sourcing partner for IVD raw materials, connecting diagnostic manufacturers and laboratories with precisely matched antibodies like this anti-DBH polyclonal. We support catecholamine biosynthesis research by offering validated antibody pairs, optimized monoclonal/polyclonal options, and bulk ancillary reagents. For rare or custom targets, our supply network can help bridge gaps from early-stage discovery to clinical application.